Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Michael S. Rafii, MD, PhD

Photo of Michael S. Rafii, MD, PhD
Title(s)Professor of Clinical Neurology
SchoolKeck School of Medicine of Usc
AddressATR 9860 Mesa Rim Road
Health Sciences Campus
San Diego CA 92121
vCardDownload vCard
    Other Positions
    Title(s)Associate Director of ACTC (Alzheimer's Clinical Trial Consortium) and Director of Medical Safety


    Collapse Overview 
    Collapse overview
    Michael S. Rafii, MD, PhD is Medical Director of the Epstein Family Alzheimer’s Therapeutic Research Institute and Professor of Clinical Neurology at the Keck School of Medicine of the University of Southern California (USC).

    Dr. Rafii earned his MD and PhD from Brown University, conducted neurogenetics research at Harvard Medical School, completed his neurology residency at the Johns Hopkins Hospital, and a fellowship in neurodegenerative diseases at the University of California, San Diego.

    Dr. Rafii is Associate Director of the NIH-funded Alzheimer’s Clinical Trials Consortium (ACTC), where he also leads the Medical Safety Unit, overseeing the safety and conduct of one of the world’s largest portfolios of Alzheimer’s disease clinical trials. He serves as Co-Director of the Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and as Co-Principal Investigator of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), two of the nation’s most influential programs advancing Alzheimer’s disease research and care.

    Dr. Rafii is internationally recognized for his work on clinical trials for Alzheimer’s disease, in particular therapies targeting the genetic form of Alzheimer’s that affects individuals with Down syndrome. He serves as Principal Investigator of ACTC-DS, a global initiative dedicated to advancing treatments for this high-risk population.

    Dr. Rafii led the Down Syndrome Biomarker Initiative (DSBI). This landmark study was the first to demonstrate that Down syndrome-related Alzheimer’s closely parallels other forms of Alzheimer’s disease, providing critical insights that have accelerated therapeutic development.

    A dedicated educator and mentor, Dr. Rafii previously served as Neurology Residency Program Director, where he helped train the next generation of neurologists. He continues to mentor medical students, postdoctoral fellows and early-career physician-scientists. He is also author of First Aid for the Neurology Boards and First Aid for the Neurology Clerkship, widely regarded as among the most trusted review books for neurology residents and medical students.

    Dr. Rafii’s work has been featured in the New York Times, Washington Post, Wall Street Journal, Chicago Tribune, the Economist and NPR. He served as Medical Advisor to the Netflix documentary Remembering Gene Wilder and to the Emmy Award–winning television series Grey’s Anatomy and This Is Us.

    Collapse Biography 
    Collapse awards and honors
    Brown University School of Medicine2002Aronson Prize for Excellence in Neuroscience
    The Johns Hopkins University/Sinai Hospital2003Intern of the Year
    The Johns Hopkins Hospital2006Preziosi Outstanding Neurology Resident Award
    The Johns Hopkins Hospital2006Alpha Omega Alpha
    LuMind Down Syndrome Research Foundation2016David Cox Award
    Alzheimer’s Association 2022Research Champion Award

    Collapse Research 
    Collapse research activities and funding
    Life?s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study
    NIH R01AG095004Aug 15, 2025 - Jul 31, 2028
    Role: Co-Principal Investigator
    Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
    NIH R01AG073979Sep 30, 2021 - Aug 31, 2026
    Role: Co-Principal Investigator
    Clinical trials to prevent Alzheimer's Disease in Down Syndrome
    NIH R33AG066543Sep 15, 2019 - Aug 31, 2025
    Role: Principal Investigator
    Clinical trials to prevent Alzheimer's Disease in Down Syndrome
    NIH R61AG066543Sep 15, 2019 - Aug 31, 2021
    Role: Principal Investigator
    ACTIVE IMMUNOTHERAPY FOR COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME
    NIH R01AG047922Aug 15, 2014 - Jun 30, 2019
    Role: Principal Investigator
    Alzheimer's Disease Cooperative Study
    NIH U19AG010483Jul 1, 1997 - Feb 28, 2021
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Electroencephalographic Normalization as a Biomarker of Clinical Recovery in Down Syndrome Regression Disorder. Ann Clin Transl Neurol. 2026 Jun 07. Santoro JD, Silverman M, Lucas MC, Yousuf MM, Otey ST, Gray SV, Jordan B, Kahan MD, Agurs LD, Das MVH, Holder D, King D, Quinn EA, Kammeyer R, Rafii MS. PMID: 42252710.
      View in: PubMed   Mentions:
    2. Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer's disease. Commun Med (Lond). 2026 Jun 02. Schlachetzki Z, Langford O, Zammit MD, Donohue MC, Zhou X, Sukreet S, Abdel-Latif S, Braunstein JB, Rissman RA, Rafii MS. PMID: 42230953.
      View in: PubMed   Mentions:
    3. Ethical challenges of capacity assessment in neurodevelopmental and intellectual disabilities. BMC Med Ethics. 2026 05 25; 27(1). Santoro JD, Kazerooni L, Lucas MC, Kingsley J, Rafii MS. PMID: 42185871; PMCID: PMC13200486.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Sleep chart of biological ageing clocks in middle and late life. Nature. 2026 May 13. MULTI Consortium, O'Toole CK, Song Z, Anagnostakis F, Yang Z, Tian YE, Duggan MR, Zou C, Leng Y, Cai Y, Bai W, Fu CHY, Rafii MS, Aisen P, Wang G, De Jager PL, Zeng J, Oh HS, Zhou X, Walker KA, Belsky DW, Zalesky A, Simonsick EM, Resnick SM, Ferrucci L, Davatzikos C, Wen J. PMID: 42129562.
      View in: PubMed   Mentions:    Fields:    
    5. Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemab. J Prev Alzheimers Dis. 2026 May 07; 13(6):100584. Rafii MS. PMID: 42102503.
      View in: PubMed   Mentions:    Fields:    
    6. Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults. J Prev Alzheimers Dis. 2026 May; 13(5):100543. Yau WW, Raman R, Chhatwal J, Pruzin JJ, Shirzadi Z, Aggarwal N, Brickman AM, Cogswell PM, Graff-Radford J, Pillai JJ, Vemuri P, Rafii MS, Yaari R, Aisen P, Sperling R, A4 and LEARN Study Teams. PMID: 41950544; PMCID: PMC13091107.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer's disease. J Prev Alzheimers Dis. 2026 Apr 01; 13(6):100547. Beyrer J, Sheff Z, Payakachat N, Chandler JM, Chen YF, Kubisiak J, Lee A, Holdridge KC, Yaari R, Aisen P, Rafii MS, Sperling RA, A4 and LEARN Study Teams. PMID: 41926844; PMCID: PMC13084671.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Precision medicine for Alzheimer's disease in Down syndrome. Alzheimers Dement. 2026 Apr; 22(4):e71398. Sukreet S, Kim EK, Petersen M, Zhang F, O'Bryant SE, Rafii MS, Rissman RA. PMID: 42002723; PMCID: PMC13092428.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder. Neurol Ther. 2026 Jun; 15(3):1099-1120. Santoro JD, Jafarpour S, Rezvan PH, Khoshnood MM, Vogel BN, Nguyen L, Kazerooni L, Spinazzi NA, Anadani N, Fisher KS, Filipink RA, Manning MA, Franklin C, Quinn EA, Rafii MS. PMID: 41795763; PMCID: PMC13172088.
      View in: PubMed   Mentions:
    10. Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome. JAMA Neurol. 2026 Mar 01; 83(3):294-296. Russell JK, Schlachetzki Z, Ances BM, Rafii MS, Alzheimer’s Biomarker Consortium–Down Syndrome Study. PMID: 41525055; PMCID: PMC12797125.
      View in: PubMed   Mentions:    Fields:    
    11. Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population. Curr Opin Neurol. 2026 Apr 01; 39(2):210-216. Russell JK, Schlachetzki Z, Rafii MS. PMID: 41709686.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Serum and cerebral folate are normal in Down Syndrome Regression Disorder. Mol Autism. 2026 Jan 28; 17(1):9. Santoro JD, Silverman M, Kazerooni L, Otey ST, Lucas MC, Yousuf MM, Koshnood MM, Spinazzi NA, Quinn EA, Franklin C, Liu TR, Jeste SS, Rafii MS. PMID: 41606634; PMCID: PMC12922418.
      View in: PubMed   Mentions:    Fields:    
    13. Brain volume trajectories in Down syndrome and autosomal dominant Alzheimer's disease. Alzheimers Dement. 2026 Jan; 22(1):e71103. Kennedy JT, Wisch JK, Boerwinkle AH, Millar PR, McKay NS, Brickman AM, Chhatwal JP, Mendez PC, Christian BT, Cohen A, Cruchaga C, Daniels A, Flores S, Handen BL, Hartley SL, Head E, Ibanez L, Krisnsky-McHale SJ, la Fougere C, Lai F, Laymon CM, Lee JH, Lee JH, Levin J, Llibre-Guerra J, Aguillon DF, Lott IT, Mapstone M, McDade E, Morris J, O'Bryant SE, Price JC, Rafii MS, Roh JH, Rosas HD, Schupf N, Supnet-Bell C, Xiong C, Zaman S, Benzinger TLS, Gordon BA, Ances BM, Alzheimer's Brain Consortium – Down Syndrome, and the Dominantly Inherited Alzheimer's Network. PMID: 41549404; PMCID: PMC12812856.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort study. Alzheimers Dement. 2026 Jan; 22(1):e71028. Russell JK, Schlachetzki Z, Conley AC, Boyd BD, Newhouse PA, Aisen PS, Rafii MS, Alzheimer's Biomarker Consortium on Down Syndrome Study. PMID: 41521149; PMCID: PMC12790954.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. "Being brave, being seen, and having your voice heard": Perspectives of self-advocates and families toward accessible and impactful research of Alzheimer's disease in down syndrome. Alzheimers Dement. 2025 Dec; 21(12):e70999. Walter S, Ptomey L, Head E, Cohen A, Briones JM, Shaw H, Carter B, Kishner J, Pestolesi W, Sciullo A, Olmstead KK, Carter A, Kishner S, Tucker AK, Pestolesi L, Briones M, Sciullo D, Sciullo K, Shaw P, Chen P, Rafii MS. PMID: 41416575; PMCID: PMC12715699.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Imaging and plasma biomarkers for pathological accumulation in Down syndrome. Brain. 2025 Nov 05. Wisch JK, Jiao Z, Kennedy JT, Cohen AD, Schlachetzki Z, Petersen M, Handen BL, Christian BT, Mapstone M, Rosas HD, Lai F, Lee JH, Krinsky-McHale SJ, Schmitt FA, Harp JP, Hom C, Lott IT, Hartley S, Zaman S, Ptomey L, Burns JM, Tudorascu D, Ibanez L, Rafii MS, Head E, Ances BM. PMID: 41205623; PMCID: PMC12917769.
      View in: PubMed   Mentions:    Fields:    
    17. Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease. JAMA Neurol. 2025 Nov 01; 82(11):1122-1134. Salvadó G, Janelidze S, Bali D, Dolado AO, Therriault J, Brum WS, Pichet Binette A, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Coomans EM, Teunissen CE, van der Flier WM, Rahmouni N, Benzinger TLS, Gispert JD, Blennow K, Doré V, Feizpour A, Rowe CC, Alcolea D, Fortea J, Villeneuve S, Johnson SC, Rosa-Neto P, Petersen RC, Jack CR, Schindler SE, Suárez-Calvet M, Ossenkoppele R, Hansson O, ADNI, ALFA, and PREVENT-AD Study Groups. PMID: 40952756; PMCID: PMC12558403.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    18. MRI-based multi-organ clocks for healthy aging and disease assessment. Nat Med. 2026 Jan; 32(1):82-92. MULTI Consortium, Cao H, Song Z, Duggan MR, Erus G, Srinivasan D, Tian YE, Bai W, Rafii MS, Aisen P, Belsky DW, Walker KA, Zalesky A, Ferrucci L, Davatzikos C, Wen J. PMID: 41102562; PMCID: PMC12823390.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. A comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials. Brain Commun. 2025; 7(6):fcaf406. Zammit M, Price J, Christian B, Rafii M, Alzheimer’s Biomarker Consortium-Down Syndrome . PMID: 41180952; PMCID: PMC12574704.
      View in: PubMed   Mentions:
    20. Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 Study. Alzheimers Dement. 2025 Oct; 21(10):e70751. Shirzadi Z, Schultz AP, Loghmani N, Yang HS, Ford J, Yaari R, Properzi M, Yau WW, Liu L, Rafii MS, Donohue MC, Brickman AM, Jack CR, Greenberg SM, Aisen P, Sperling RA, Chhatwal JP, A4 Study Team. PMID: 41085172; PMCID: PMC12519508.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    21. Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease. Ann Neurol. 2025 12; 98(6):1237-1248. Abdelmoity O, Wisch JK, Kennedy JT, Goyal M, Vlassenko A, Flores S, Handen BL, Head E, Keator D, Rafii MS, Lao P, Lai F, Rosas HD, Hartley SL, Zaman S, Brickman AM, Tudorascu D, Lee JH, Allegri RF, Keefe S, la Fougere C, Llibre-Guerra J, Ikeuchi T, Morris JC, Roh JH, Day GS, Levin J, Schofield PR, Gordon BA, Benzinger TLS, Ances BM, Alzheimer's Biomarker Consortium-Down Syndrome and the Dominantly Inherited Alzheimer Network. PMID: 40977577; PMCID: PMC12903563.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. Lancet Neurol. 2025 Sep; 24(9):753-762. Rafii MS, Schlachetzki Z, Barroeta I, Head E, Fortea J, Ances BM. PMID: 40818475.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Sleep chart of biological aging clocks across organs and omics. medRxiv. 2025 Aug 11. MULTI study, O'Toole CK, Song Z, Anagnostakis F, Yang Z, Tian YE, Duggan MR, Zou C, Leng Y, Cai Y, Bai W, Fu CHY, Rafii MS, Aisen P, Wang G, De Jager PL, Zeng J, Oh HS, Zhou X, Walker KA, Belsky DW, Zalesky A, Simonsick EM, Resnick SM, Ferrucci L, Davatzikos C, Wen J. PMID: 40832429; PMCID: PMC12363694.
      View in: PubMed   Mentions:
    24. Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives. Alzheimers Dement. 2025 08; 21(8):e70536. Iwatsubo T, Sperling RA, Algeciras-Schimnich A, Arai H, Barron AM, Benzinger TLS, Carrillo MC, Chen C, Choi SH, Fontana IC, Graff-Radford J, Grill JD, Heidebrink J, Hu CJ, Ihara R, Ikeuchi T, Iwata A, Ip FCF, Fitri FI, Jack CR, Jeong JH, Jia J, Kandiah N, Kim S, Kowa H, La Joie R, Niimi Y, Noritake R, Okonkwo OC, Palmqvist S, Rafii MS, Raman R, Shen Y, Simuni T, Snyder HM, Sriwannopas O, Stoeckel LE, van der Flier WM, Wang H, Wilcock DM, Zetterberg H, Zhou J, Mahinrad S, Sexton CE. PMID: 40760693; PMCID: PMC12321508.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Targeting tau for Alzheimers disease through OGA inhibition. J Prev Alzheimers Dis. 2025 Sep; 12(8):100309. Rafii MS. PMID: 40707335; PMCID: PMC12413698.
      View in: PubMed   Mentions:    Fields:    
    26. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2025 09; 21(9):490-498. Rafii MS, Aisen PS. PMID: 40691719.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    27. Multi-organ MRI digitizes biological aging clocks across proteomics, metabolomics, and genetics. medRxiv. 2025 Jul 11. MULTI Consortium, Cao H, Song Z, Duggan MR, Erus G, Srinivasan D, Tian YE, Bai W, Rafii MS, Aisen P, Belsky DW, Walker KA, Zalesky A, Ferrucci L, Davatzikos C, Wen J. PMID: 40672508; PMCID: PMC12265779.
      View in: PubMed   Mentions:
    28. Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference. Alzheimers Dement. 2025 07; 21(7):e70309. Falgàs N, Maure-Blesa L, Ances B, Flores-Aguilar L, Hartley S, Hassenstab J, Iulita MF, Janicki M, Koenig K, Lao P, Levin J, McDade E, Meijer L, Rafii MS, Snyder HM, Sánchez-Valle R, Fortea J, DSAD-ADAD conference group, Arriola Infante J, Balasa M, Barroeta I, Barthelemy R N, Bejanin A, Benejam B, Bosch B, Bradshaw A, Carmona-Iragui M, Cohen A, Comas Albertí A, Csincsik L, Cuello AC, Del Hoyo Soriano L, Dijkstra J, Edwards N, Giménez S, Gonzalez-Ortiz F, Gordon B, Gutiérrez Fernández S, Handen B, Jacob C, Johnson E, Johansson C, Lladó A, Lleó A, Morabito S, Morcillo-Nieto AO, Montoliu-Gaya L, Okafor M, Pérez-Millan A, Potier MC, Ringman J, Rodríguez-Baz Í, Rubenstein E, Ryan NS, Strydom A, Vaqué-Alcázar L, Vermunt L, Videla Toro L, Zaman S. PMID: 40604347; PMCID: PMC12221810.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. Alzheimers Dement. 2025 06; 21(6):e70258. Barroeta I, Videla L, Carmona-Iragui M, Fortea J, Rafii MS. PMID: 40528298; PMCID: PMC12173829.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. The history of Down syndrome-associated Alzheimer's disease; past, present, and future. Alzheimers Dement. 2025 06; 21(6):e70158. Maure-Blesa L, Carmona-Iragui M, Lott I, Head E, Wisniewski T, Rafii MS, Espinosa J, Flórez J, Mobley WC, Holland A, Strydom A, Zaman S, Fortea J. PMID: 40469048; PMCID: PMC12138279.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Relationship between use of anti-platelet agents, oral anti-coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults. Alzheimers Dement. 2025 05; 21(5):e70167. Gay MD, Baldaranov D, Donohue MC, Jack CR, Sperling RA, Aisen PS, Rafii MS. PMID: 40356042; PMCID: PMC12069015.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Brain cholinergic terminal density utilizing [18F]-fluoroethoxybenzovesamicol PET in adults with Down's syndrome: Relationship to amyloid PET and cognitive performance. Alzheimers Dement. 2025 04; 21(4):e70134. Russell JK, Conley AC, Boyd BD, Begnoche JP, Schlossberg R, Stranick A, Rosenberg AJ, Acosta LMY, Martin D, Neal Y, Rafii MS, Dumas J, Newhouse PA. PMID: 40189807; PMCID: PMC11972980.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Reflecting on progress, envisioning the future for research in Down syndrome. Lancet. 2025 Mar 20. Santoro JD, Rafii MS. PMID: 40122085.
      View in: PubMed   Mentions:    Fields:    
    34. A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials. medRxiv. 2025 Mar 19. Zammit MD, Price JC, Christian BT, Rafii MS, Alzheimer’s Biomarker Consortium – Down Syndrome. PMID: 40166579; PMCID: PMC11957079.
      View in: PubMed   Mentions:
    35. Clinical and neuropathological analysis of Down syndrome over 7 decades of life. J Neuropathol Exp Neurol. 2025 Feb 01; 84(2):168-173. Sukreet S, Goodwill VS, Ngolab J, Kim HY, Leisher S, Salehi S, Rafii MS, Hiniker A, Rissman RA. PMID: 39471466; PMCID: PMC11747220.
      View in: PubMed   Mentions:    Fields:    
    36. Differences in cholinergic terminal density in adults with Down syndrome compared to neurotypical controls measured by [18F]-fluoroethoxybenzovesamicol positron emission tomography imaging. Neurobiol Aging. 2025 04; 148:50-60. Russell JK, Conley AC, Boyd BD, Begnoche JP, Schlossberg R, Stranick A, Rosenberg AJ, Acosta LMY, Martin D, Neal Y, Kanel P, Albin RL, Rafii MS, Dumas J, Newhouse PA. PMID: 39914061; PMCID: PMC11981543.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    37. Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials. J Prev Alzheimers Dis. 2025 Jan; 12(1):100002. Jimenez-Maggiora GA, Donohue MC, Rafii MS, Raman R, Aisen PS. PMID: 39800465; PMCID: PMC12184043.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder. Sci Rep. 2024 12 28; 14(1):30865. Santoro JD, Jafarpour S, Keehan L, Khoshnood MM, Kazerooni L, Boyd NK, Vogel BN, Nguyen L, Manning M, Nagesh D, Spinazzi NA, Besterman AD, Quinn EA, Rafii MS. PMID: 39730779; PMCID: PMC11680819.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. Effects of the therapeutic correction of U1 snRNP complex on Alzheimer's disease. Sci Rep. 2024 12 03; 14(1):30085. Leal CBQS, Zimmer CGM, Sinatti VVC, Soares ES, Poppe B, de Wiart AC, Chua XY, da Silva RV, Magdesian MH, Rafii MS, Buée L, Bottos RM. PMID: 39627450; PMCID: PMC11615310.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    40. The amyloid clock: mapping Alzheimer's disease in Down syndrome. Lancet Neurol. 2024 Dec; 23(12):1173-1174. Rafii MS. PMID: 39577903.
      View in: PubMed   Mentions: 1     Fields:    
    41. The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome. Alzheimers Dement. 2025 01; 21(1):e14359. Boerwinkle AH, Wisch JK, Handen BL, Head E, Mapstone M, Rafii MS, O'Bryant SE, Krinsky-McHale SJ, Lai F, Rosas HD, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Ances BM, Alzheimer's Biomarker Consortium-Down Syndrome. PMID: 39535359; PMCID: PMC11782213.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Age-Related Changes in the Cholinergic System in Adults with Down Syndrome Assessed Using [18F]-Fluoroethoxybenzovesamicol Positron Emission Tomography Imaging. medRxiv. 2024 Nov 01. Russell JK, Conley AC, Boyd BD, Begnoche JP, Schlossberg R, Stranick A, Rosenberg AJ, Acosta LMY, Martin D, Neal Y, Kanel P, Albin RL, Rafii MS, Dumas J, Newhouse PA. PMID: 39574852; PMCID: PMC11581087.
      View in: PubMed   Mentions:
    43. The Alzheimer's Disease Neuroimaging Initiative Clinical Core. Alzheimers Dement. 2024 10; 20(10):7361-7368. Aisen PS, Donohue MC, Raman R, Rafii MS, Petersen RC, Alzheimer's Disease Neuroimaging Initiative. PMID: 39136045; PMCID: PMC11485391.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Revised criteria for the diagnosis and staging of Alzheimer's disease. Nat Med. 2024 08; 30(8):2121-2124. Jack CR, Andrews SJ, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. PMID: 38942991; PMCID: PMC11630478.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    45. Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid. Alzheimers Dement. 2024 08; 20(8):5570-5577. Krasny S, Yan C, Hartley SL, Handen BL, Wisch JK, Boehrwinkle AH, Ances BM, Rafii MS, ABC-DS consortium. PMID: 38940611; PMCID: PMC11350128.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    46. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024 08; 20(8):5143-5169. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. PMID: 38934362; PMCID: PMC11350039.
      View in: PubMed   Mentions: 987     Fields:    Translation:Humans
    47. De novo variants in immune regulatory genes in Down syndrome regression disorder. J Neurol. 2024 Aug; 271(8):5567-5576. Jafarpour S, Banerjee AK, Khoshnood MM, Vogel BN, Boyd NK, Nguyen L, Partridge R, Santoro SL, Gombolay GY, Fisher KS, de Asua DR, Del Ortega MC, Franklin C, Rafii MS, Santoro JD. PMID: 38909119; PMCID: PMC11319504.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    48. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2024 05; 23(5):500-510. Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM, Alzheimer's Biomarker Consortium-Down syndrome, Dominantly Inherited Alzheimer Network. PMID: 38631766; PMCID: PMC11209765.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    49. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach. Alzheimers Dement (Amst). 2024 Apr-Jun; 16(2):e12580. Sukreet S, Rafii MS, Rissman RA. PMID: 38623383; PMCID: PMC11016820.
      View in: PubMed   Mentions: 8  
    50. Addressing challenges in health care and research for people with Down syndrome. Lancet. 2024 05 11; 403(10439):1830-1833. Fortea J, McGlinchey E, Espinosa JM, Rafii MS. PMID: 38521088.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    51. Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder. Ann Clin Transl Neurol. 2024 04; 11(4):1034-1045. Santoro JD, Khoshnood MM, Jafarpour S, Nguyen L, Boyd NK, Vogel BN, Kammeyer R, Patel L, Manning MA, Rachubinski AL, Filipink RA, Baumer NT, Santoro SL, Franklin C, Tamrazi B, Yeom KW, Worley G, Espinosa JM, Rafii MS. PMID: 38375538; PMCID: PMC11021615.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder. Am J Med Genet A. 2024 05; 194(5):e63524. Santoro JD, Jafarpour S, Khoshnood MM, Boyd NK, Vogel BN, Nguyen L, Saucier LE, Partridge R, Tiongson E, Ramos-Platt L, Nagesh D, Ho E, Rosser T, Ahsan N, Mitchell WG, Rafii MS. PMID: 38169137; PMCID: PMC13127129.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial. J Prev Alzheimers Dis. 2024; 11(4):857-868. Yaari R, Holdridge KC, Mancini M, Rafii MS, Case M, Battioui C, Sims JR, Aisen PS, Sperling RA. PMID: 39044494; PMCID: PMC11266256.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    54. Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease. J Prev Alzheimers Dis. 2024; 11(4):869-873. Shirzadi Z, Schultz AP, Properzi M, Yaari R, Yau WW, Brickman AM, Rafii MS, Donohue MC, Ernstrom K, Wang S, Jack CR, Greenberg SM, Raman R, Aisen P, Sperling RA, Chhatwal JP. PMID: 39044495; PMCID: PMC11266366.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    55. Estimating Socio-Economic Status for Alzheimer's Disease Trials. J Prev Alzheimers Dis. 2024; 11(5):1418-1425. Rentz DM, Grill JD, Molina-Henry DP, Jicha GA, Rafii MS, Liu A, Sperling RA, Aisen PS, Raman R. PMID: 39350389; PMCID: PMC11436426.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Down Syndrome in a New Era for Alzheimer Disease. JAMA. 2023 12 12; 330(22):2157-2158. Rafii MS, Fortea J. PMID: 37991807; PMCID: PMC11324235.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    57. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimers Dement. 2024 02; 20(2):1214-1224. Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, Braunstein JB, Irizarry M, Johnson KA, Aisen PS, Sperling RA, AHEAD 3-45 Study team. PMID: 37932961; PMCID: PMC10916957.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    58. Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder. J Neurodev Disord. 2023 10 25; 15(1):35. Boyd NK, Nguyen J, Khoshnood MM, Jiang T, Nguyen L, Mendez L, Spinazzi NA, Manning MA, Rafii MS, Santoro JD. PMID: 37880588; PMCID: PMC10599027.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Alternative Diagnoses in the Work Up of Down Syndrome Regression Disorder. J Autism Dev Disord. 2025 Jun; 55(6):2085-2091. Santoro JD, Khoshnood MM, Nguyen L, Vogel BN, Boyd NK, Paulsen KC, Rafii MS. PMID: 37584771.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    60. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl Psychiatry. 2023 08 08; 13(1):276. Santoro JD, Spinazzi NA, Filipink RA, Hayati-Rezvan P, Kammeyer R, Patel L, Sannar EA, Dwyer L, Banerjee AK, Khoshnood M, Jafarpour S, Boyd NK, Partridge R, Gombolay GY, Christy AL, Real de Asua D, Del Carmen Ortega M, Manning MA, Van Mater H, Worley G, Franklin C, Stanley MA, Brown R, Capone GT, Quinn EA, Rafii MS. PMID: 37553347; PMCID: PMC10409776.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    61. Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. CNS Drugs. 2023 08; 37(8):671-677. Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS. PMID: 37470978; PMCID: PMC10439019.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    62. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023 09 21; 389(12):1096-1107. Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS, A4 Study Team. PMID: 37458272; PMCID: PMC10559996.
      View in: PubMed   Mentions: 190     Fields:    Translation:Humans
    63. Detection and treatment of Alzheimer's disease in its preclinical stage. Nat Aging. 2023 05; 3(5):520-531. Rafii MS, Aisen PS. PMID: 37202518; PMCID: PMC11110912.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    64. Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12431. Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS. PMID: 37091309; PMCID: PMC10113881.
      View in: PubMed   Mentions: 6  
    65. Adverse childhood experiences and the development of Down syndrome regression disorder. Am J Med Genet A. 2023 07; 191(7):1769-1782. Wang S, Patel L, Sannar EA, Khoshnood M, Boyd NK, Mendez L, Spinazzi NA, Quinn EA, Rafii MS, Santoro JD. PMID: 37017126.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    66. Immunotherapy Responsiveness and Risk of Relapse in Down Syndrome Regression Disorder. Res Sq. 2023 Feb 13. Santoro J, Spinazzi N, Filipink R, Hayati-Rezvan P, Kammeyer R, Patel L, Sannar E, Dwyer L, Banerjee A, Khoshnood M, Jafarpour S, Boyd N, Partridge R, Gombolay G, Christy A, Real de Asua D, Del Carmen Ortega M, Manning M, Van Mater H, Worley G, Franklin C, Stanley M, Brown R, Capone G, Quinn E, Rafii M. PMID: 36824719; PMCID: PMC9949176.
      View in: PubMed   Mentions:
    67. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2023 01; 22(1):55-65. Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant S, Lai F, Rosas HD, Lee JH, Silverman W, Brickman AM, Chhatwal JP, Cruchaga C, Perrin RJ, Xiong C, Hassenstab J, McDade E, Bateman RJ, Ances BM, Alzheimer's Biomarker Consortium-Down Syndrome, Dominantly Inherited Alzheimer Network. PMID: 36517172; PMCID: PMC9979840.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    68. Editorial: Appropriate Use Recommendations for Lecanemab. J Prev Alzheimers Dis. 2023; 10(3):356. Rafii MS. PMID: 37357273.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    69. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023 04; 19(4):1227-1233. Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, Johnson KA, Aisen PS. PMID: 35971310; PMCID: PMC9929028.
      View in: PubMed   Mentions: 146     Fields:    Translation:Humans
    70. Assessment and Diagnosis of Down Syndrome Regression Disorder: International Expert Consensus. Front Neurol. 2022; 13:940175. Santoro JD, Patel L, Kammeyer R, Filipink RA, Gombolay GY, Cardinale KM, Real de Asua D, Zaman S, Santoro SL, Marzouk SM, Khoshnood M, Vogel BN, Tanna R, Pagarkar D, Dhanani S, Ortega MDC, Partridge R, Stanley MA, Sanders JS, Christy A, Sannar EM, Brown R, McCormick AA, Van Mater H, Franklin C, Worley G, Quinn EA, Capone GT, Chicoine B, Skotko BG, Rafii MS. PMID: 35911905; PMCID: PMC9335003.
      View in: PubMed   Mentions: 27  
    71. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. J Neurodev Disord. 2022 06 03; 14(1):35. Santoro JD, Partridge R, Tanna R, Pagarkar D, Khoshnood M, Rehmani M, Kammeyer RM, Gombolay GY, Fisher K, Conravey A, El-Dahr J, Christy AL, Patel L, Manning MA, Van Mater H, Rafii MS, Quinn EA. PMID: 35659536; PMCID: PMC9164321.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    72. Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. JAMA Neurol. 2022 06 01; 79(6):565-574. Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, Sabbagh MN, Yuan SH, Rissman RA, Pulsifer M, Evans C, Evans AC, Beth G, Fournier N, Gray JA, Dos Santos AM, Hliva V, Vukicevic M, Kosco-Vilbois M, Streffer J, Pfeifer A, Feldman HH. PMID: 35532913; PMCID: PMC9086937.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    73. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022 07; 18(7):389-399. Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. PMID: 35379951; PMCID: PMC8978175.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    74. Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. J Neurodev Disord. 2022 03 23; 14(1):22. Baumer NT, Becker ML, Capone GT, Egan K, Fortea J, Handen BL, Head E, Hendrix JE, Litovsky RY, Strydom A, Tapia IE, Rafii MS. PMID: 35321660; PMCID: PMC8942061.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    75. Development of treatments for Down syndrome. Lancet Neurol. 2022 01; 21(1):22-23. Rafii MS. PMID: 34942129; PMCID: PMC11108095.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    76. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021 11; 20(11):930-942. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. PMID: 34687637; PMCID: PMC9387748.
      View in: PubMed   Mentions: 200     Fields:    Translation:Humans
    77. Increased Autoimmunity in Individuals With Down Syndrome and Moyamoya Disease. Front Neurol. 2021; 12:724969. Santoro JD, Lee S, Wang AC, Ho E, Nagesh D, Khoshnood M, Tanna R, Durazo-Arvizu RA, Manning MA, Skotko BG, Steinberg GK, Rafii MS. PMID: 34566869; PMCID: PMC8455812.
      View in: PubMed   Mentions: 17  
    78. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021; 13(1):e12199. Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA. PMID: 34430703; PMCID: PMC8369843.
      View in: PubMed   Mentions: 26  
    79. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021 03 01; 78(3):293-301. Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, Thipphawong J, Saad ZS, Kolb H, Rofael H, Sanga P, Romano G. PMID: 33464300; PMCID: PMC7816119.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    80. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome. J Prev Alzheimers Dis. 2021; 8(1):48-51. Rafii MS, Zaman S, Handen BL. PMID: 33336224; PMCID: PMC8279390.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    81. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. J Alzheimers Dis. 2021; 79(2):671-681. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee JH, Handen B, Hartley S, Fortea J, O'Bryant S, Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS). PMID: 33337378; PMCID: PMC8273927.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    82. The search for Alzheimer disease therapeutics - same targets, better trials? Nat Rev Neurol. 2020 11; 16(11):597-598. Rafii MS, Aisen PS. PMID: 32963375.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    83. The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020; 12(1):e12062. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, O'Bryant S. PMID: 33134477; PMCID: PMC7588820.
      View in: PubMed   Mentions: 28  
    84. Neurologic complications of Down syndrome: a systematic review. J Neurol. 2021 Dec; 268(12):4495-4509. Santoro JD, Pagarkar D, Chu DT, Rosso M, Paulsen KC, Levitt P, Rafii MS. PMID: 32920658.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    85. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020 09 01; 77(9):1099-1109. Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. PMID: 32568367; PMCID: PMC7309571.
      View in: PubMed   Mentions: 197     Fields:    Translation:Humans
    86. Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. CNS Drugs. 2020 08; 34(8):785-794. Rafii MS. PMID: 32506291; PMCID: PMC7395870.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    87. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. Alzheimers Dement (Amst). 2020; 12(1):e12039. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Ances BM, Wang MC, Tycko B, Lee JH, O'Bryant S, Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS). PMID: 32626817; PMCID: PMC7327223.
      View in: PubMed   Mentions: 18  
    88. Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimers Dement. 2020 07; 16(7):1065-1077. Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. PMID: 32544310; PMCID: PMC8865308.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    89. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimers Dement. 2020 05; 16(5):797-803. Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS, Alzheimer's Disease Neuroimaging Initiative. PMID: 32270600; PMCID: PMC8317593.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    90. Down syndrome. Nat Rev Dis Primers. 2020 02 06; 6(1):9. Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. PMID: 32029743; PMCID: PMC8428796.
      View in: PubMed   Mentions: 456     Fields:    Translation:Humans
    91. Diminished Blood Pressure Profiles in Children With Down Syndrome. Hypertension. 2020 03; 75(3):819-825. Santoro JD, Lee S, Mlynash M, Mayne EW, Rafii MS, Skotko BG. PMID: 31928114.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    92. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Oct 01; 76(10):1219-1229. van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. PMID: 31329216; PMCID: PMC6646979.
      View in: PubMed   Mentions: 80     Fields:    
    93. Predicting the course of Alzheimer's progression. Brain Inform. 2019 Jun 28; 6(1):6. Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC, Alzheimer’s Disease Neuroimaging Initiative. PMID: 31254120; PMCID: PMC6598897.
      View in: PubMed   Mentions: 20  
    94. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs. 2019 02; 33(2):99-106. Rafii MS, Aisen PS. PMID: 30560544; PMCID: PMC6367028.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    95. Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurol. 2019 02 01; 76(2):142-143. Rafii MS, Santoro SL. PMID: 30452497.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    96. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2019; 70(1):131-138. Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA. PMID: 31156181.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    97. Down syndrome. Handb Clin Neurol. 2019; 167:321-336. Rafii MS, Kleschevnikov AM, Sawa M, Mobley WC. PMID: 31753140.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    98. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. Dev Neurobiol. 2019 07; 79(7):711-715. Rafii MS. PMID: 30536948.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    99. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (Amst). 2018; 10:657-668. Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. PMID: 30456292; PMCID: PMC6234901.
      View in: PubMed   Mentions: 13  
    100. Diagnostic biomarkers of Alzheimer's disease in Down syndrome. Lancet Neurol. 2018 10; 17(10):831-832. Rafii MS. PMID: 30172623.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neurodegener Dis. 2018; 18(4):173-190. Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. PMID: 30089306; PMCID: PMC6314496.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    102. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 07 01; 75(7):834-841. Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS, AAV2-NGF Study Team. PMID: 29582053; PMCID: PMC5885277.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCells
    103. Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017 05; 122(3):247-281. Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, d'Ardhuy XL, Capone G, Conners FA, Mervis CB, Abbeduto L, Rafii MS, Krinsky-McHale SJ, Urv T, Outcome Measures Working Group. PMID: 28452584; PMCID: PMC5424621.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    104. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Alzheimers Dement. 2017 Nov; 13(11):1251-1260. Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinós MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, Bosch B, Lladó A, Rafii MS, Head E, Molinuevo JL, Blesa R, Videla S, Lleó A, Sánchez-Valle R, Fortea J. PMID: 28463681; PMCID: PMC5660938.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    105. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 02; 88(18):1768-1775. Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS, Alzheimer's Disease Cooperative Study. PMID: 28381506; PMCID: PMC5409846.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    106. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2017; 60(2):439-450. Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC, Down Syndrome Biomarker Initiative and the Alzheimer’s Disease Neuroimaging Initiative. PMID: 28946567.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    107. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. J Alzheimers Dis. 2017; 58(2):401-411. Rafii MS, Skotko BG, McDonough ME, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT, ELND005-DS Study Group. PMID: 28453471; PMCID: PMC5777855.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    108. Targeting tau protein in Alzheimer's disease. Lancet. 2016 12 10; 388(10062):2842-2844. Rafii MS. PMID: 27863808.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    109. Improving Memory and Cognition in Individuals with Down Syndrome. CNS Drugs. 2016 07; 30(7):567-73. Rafii MS. PMID: 27272473.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    110. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimers Dement (N Y). 2016 Jun; 2(2):69-81. Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. PMID: 28642933; PMCID: PMC5477635.
      View in: PubMed   Mentions: 37  
    111. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. PMID: 26441570; PMCID: PMC4568340.
      View in: PubMed   Mentions: 54  
    112. Advances in Alzheimer's disease drug development. BMC Med. 2015 Mar 25; 13:62. Rafii MS, Aisen PS. PMID: 25857341; PMCID: PMC4373002.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    113. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome? Alzheimers Res Ther. 2014; 6(5-8):60. Rafii MS. PMID: 25478025; PMCID: PMC4255529.
      View in: PubMed   Mentions: 4     Fields:    
    114. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT. PMID: 24411134.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansCellsCTClinical Trials
    115. Preclinical Alzheimer's disease therapeutics. J Alzheimers Dis. 2014; 42 Suppl 4:S545-9. Rafii MS. PMID: 25079804.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    116. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. PMID: 24164929; PMCID: PMC5351414.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    117. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013 Aug; 88(8):831-40. Moran JA, Rafii MS, Keller SM, Singh BK, Janicki MP, American Academy of Developmental Medicine and Dentistry, Rehabilitation Research and Training Center on Aging With Developmental Disabilities, University of , American Association on Intellectual and Developmental Disabilities. PMID: 23849993.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    118. Update on Alzheimer's disease therapeutics. Rev Recent Clin Trials. 2013 Jun; 8(2):110-8. Rafii MS. PMID: 23859061.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    119. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 09; 11(9):655-6. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. PMID: 22935789.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic Health
    120. Comparison of the memory performance index with standard neuropsychological measures of cognition. Am J Alzheimers Dis Other Demen. 2011 05; 26(3):235-9. Rafii MS, Taylor C, Coutinho A, Kim K, Galasko D. PMID: 21406427; PMCID: PMC3568924.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    121. Functional brain imaging in the clinical assessment of consciousness. PLoS Biol. 2010 Nov 30; 8(11):e1000548. Rafii MS, Brewer JB. PMID: 21151340; PMCID: PMC2994656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials. 2010 Jan; 5(1):57-62. Rafii MS. PMID: 20205688.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    123. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2009 Apr-Jun; 23(2):139-45. Kovacevic S, Rafii MS, Brewer JB, Alzheimer's Disease Neuroimaging Initiative. PMID: 19474571; PMCID: PMC2688740.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    124. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19; 7:7. Rafii MS, Aisen PS. PMID: 19228370; PMCID: PMC2649159.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    125. Primary care screening for dementia and mild cognitive impairment. JAMA. 2008 Mar 12; 299(10):1132; author reply 1133-4. Rafii MS, Galasko D. PMID: 18334686.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    126. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol. 2006 Nov; 209(2):439-47. Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. PMID: 16883602; PMCID: PMC2929672.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    127. Case 14: a woman with bilateral Bell's palsy. MedGenMed. 2006 Oct 31; 8(4):23. Rafii MS. PMID: 17415306; PMCID: PMC1868343.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    128. Compendium of cerebrovascular diseases. Int Rev Psychiatry. 2006 Oct; 18(5):395-407. Rafii MS, Hillis AE. PMID: 17085359.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    129. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. 2006 Aug; 20(10):1724-6. Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. PMID: 16807372; PMCID: PMC3056440.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    130. Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology. 2005 Dec 27; 65(12):1906. Rafii MS, Koenig M, Ziai WC. PMID: 16380611.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Michael's Networks
    Concepts (264)
    Derived automatically from this person's publications.
    _
    Co-Authors (52)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _